8-K: Cytek Biosciences Reports Mixed Q2 2024 Results: Revenue Declines in US Offset by Growth in EMEA and APAC

Cytek Biosciences reported a 6% year-over-year decrease in revenue for the second quarter of 2024, primarily due to weakness in the U.S. market, despite growth in other regions and its service business.

Summary

• Cytek Biosciences announced its financial results for the second quarter of 2024, with total revenue reaching $46.6 million.
• This represents a 4% increase compared to the first quarter of 2024, but a 6% decrease compared to the second quarter of 2023.
• The company experienced strong double-digit revenue growth in EMEA and APAC, as well as in its service business, but this was offset by a decline in U.S. instrument sales, particularly to academic and government customers.
• For the first half of 2024, total revenue grew by 5% compared to the first half of 2023.
• Gross profit for the quarter was $25.4 million, a 10% decrease year-over-year, with a GAAP gross profit margin of 55% and an adjusted gross profit margin of 58%.
• Operating expenses decreased by 9% to $34.0 million, driven by reduced research and development and sales and marketing expenses.
• The company reported a net loss of $10.4 million for the quarter, compared to a net loss of $4.4 million in the same period last year.
• Adjusted EBITDA was $2.9 million, compared to $1.5 million in the second quarter of 2023.
• Cytek's installed base of instruments reached 2,656 units, with 147 units added in the second quarter.
• The company repurchased $2.7 million of its stock during the quarter under a new $50 million share repurchase program.
• Cash and marketable securities totaled $277.2 million as of June 30, 2024, an increase of $6.8 million from the end of the previous quarter.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to the year-over-year revenue decline, increased net loss, and weakness in the U.S. market. However, there are some positives such as growth in other regions, improved EBITDA, and a stock repurchase program.

Positives

• Cytek experienced strong year-over-year double-digit revenue growth in EMEA and APAC regions.
• The service business also showed strong growth compared to the second quarter of 2023.
• The company's installed base of instruments continues to grow, reaching 2,656 units.
• Cytek successfully repurchased $2.7 million of its stock, indicating confidence in its value.
• Adjusted EBITDA improved to $2.9 million, up from $1.5 million in the same quarter last year.
• Operating expenses decreased by 9%, showing improved cost management.
• The company's cash and marketable securities increased by $6.8 million in the quarter.
• Cytek launched Enhanced Small Particle (ESP) detection technology, expanding its product capabilities.

Negatives

• Total revenue decreased by 6% compared to the second quarter of 2023.
• The company experienced a decline in U.S. instrument sales, particularly among academic and government customers.
• Gross profit decreased by 10% year-over-year.
• GAAP gross profit margin decreased to 55% from 57% in the same quarter last year.
• The company reported a net loss of $10.4 million, compared to a net loss of $4.4 million in the second quarter of 2023.
• Research and development expenses decreased from $12.1 million to $10.0 million.

Risks

• The company is facing headwinds in the U.S. market, particularly with academic and government customers.
• There is a risk that the decline in U.S. instrument sales could continue to impact overall revenue.
• The company's gross profit margin has decreased, which could affect profitability.
• The company is experiencing a net loss, which could impact investor confidence.
• The company's future performance is subject to various risks, including global economic conditions, competition, and market acceptance of its products.

Future Outlook

Cytek narrowed its 2024 revenue guidance to a range of $203 million to $210 million, representing growth of 5% to 9% over 2023. The company expects to report a net loss in the single-digit millions for the full year 2024 and anticipates generating positive cash flow from operations in 2024.

Management Comments

• Dr. Wenbin Jiang, CEO of Cytek Biosciences, stated that the company posted strong year-over-year double-digit revenue growth in EMEA and APAC as well as in its service business worldwide.
• Dr. Jiang also noted that this performance was offset by a decline in U.S. instrument sales, particularly among academic and government customers.
• Despite the headwinds in the U.S. market, management believes the fundamental drivers of long-term growth remain in place and the underlying opportunity for their products remains strong.
• Management remains focused on executing their business strategy and delivering durable growth and profitability and strong value to their customers and shareholders.

Industry Context

The results reflect a mixed performance in the life sciences tools sector, where companies are experiencing varying regional growth patterns. Cytek's challenges in the U.S. market contrast with its success in EMEA and APAC, highlighting the importance of geographic diversification. The launch of new technologies like ESP detection is crucial for maintaining a competitive edge in the cell analysis market.

Comparison to Industry Standards

• Compared to companies like Bio-Rad Laboratories and Thermo Fisher Scientific, Cytek's revenue growth is lower this quarter, but its focus on cell analysis and its proprietary FSP technology differentiate it.
• While Bio-Rad and Thermo Fisher have broader product portfolios, Cytek's specialization in high-resolution cell analysis positions it well in a niche market.
• The decline in US sales is a concern, as other companies in the sector have shown more resilience in the US market.
• Cytek's adjusted EBITDA growth is a positive sign, but its net loss is a concern compared to more profitable peers.
• The company's installed base growth is a positive indicator of market adoption, but it needs to translate into stronger revenue growth.

Stakeholder Impact

• Shareholders may be concerned about the decrease in revenue and the increased net loss.
• Employees may be affected by the company's cost-cutting measures, such as reduced research and development and sales and marketing expenses.
• Customers may benefit from the launch of new technologies like ESP detection.
• Suppliers may be impacted by changes in the company's purchasing patterns.
• Creditors may be concerned about the company's increased net loss.

Next Steps

• Cytek will host a conference call to discuss its second quarter 2024 financial results on August 6, 2024.
• The company will continue to execute its business strategy and focus on delivering durable growth and profitability.
• Cytek will continue to monitor its website, LinkedIn page, and X account for updates.

Key Dates

Keywords

Cytek Biosciences, cell analysis, flow cytometry, financial results, revenue, EBITDA, gross profit, instrument sales, stock repurchase, ESP detection